Search Result

Results for "

IgG4κ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (4) Apoptosis (3) c-Met/HGFR (1) CD19 (1) CD22 (2) CD28 (4) CD3 (4) CD47 (2) CD73 (1) CXCR (3) EGFR (2) Factor Xa (2) Fc Receptor (FcR) (1) Ferroportin (1) Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1) IFNAR (1) IGF-1R (1) Interleukin Related (13) LAG-3 (5) Mucin (1) Natriuretic Peptide Receptor (NPR) (1) Neuropeptide Y Receptor (1) Orexin Receptor (OX Receptor) (2) PACAP Receptor (1) PAI-1 (1) PCSK9 (1) PD-1/PD-L1 (10) PSMA (1) RANKL/RANK (1) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) TGF-β Receptor (1) Thrombin (1) TNF Receptor (6) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (11) VEGFR (2)
By Research Areas:	Cancer (24) Cardiovascular Disease (6) Inflammation/Immunology (75)

By Targets:

ADC Antibody (4)

Apoptosis (3)

c-Met/HGFR (1)

CD19 (1)

CD22 (2)

CD28 (4)

CD3 (4)

CD47 (2)

CD73 (1)

CXCR (3)

EGFR (2)

Factor Xa (2)

Fc Receptor (FcR) (1)

Ferroportin (1)

Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1)

IFNAR (1)

IGF-1R (1)

Interleukin Related (13)

LAG-3 (5)

Mucin (1)

Natriuretic Peptide Receptor (NPR) (1)

Neuropeptide Y Receptor (1)

Orexin Receptor (OX Receptor) (2)

PACAP Receptor (1)

PAI-1 (1)

PCSK9 (1)

PD-1/PD-L1 (10)

PSMA (1)

RANKL/RANK (1)

Ser/Thr Protease (2)

Small Interfering RNA (siRNA) (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Thrombin (1)

TNF Receptor (6)

Toll-like Receptor (TLR) (1)

Transmembrane Glycoprotein (11)

VEGFR (2)

By Research Areas:

Cancer (24)

Cardiovascular Disease (6)

Inflammation/Immunology (75)

Inhibitors & Agonists

105

Inhibitory Antibodies

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

Nadecnemab	TGF-β Receptor	Inflammation/Immunology
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .

Zadoprubart	CD28	Inflammation/Immunology
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Nebaprubart	Fc Receptor (FcR)	Inflammation/Immunology
Nebaprubart is a humanized IgG4κ antibody targeting FCAR/CD89. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

Ponumkibart	Interleukin Related	Inflammation/Immunology
Ponumkibart is a humanized IgG4κ antibody targeting IL-17RB. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

Liscastobart	PD-1/PD-L1	Cancer
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

Ticalicibart	PCSK9	Cardiovascular Disease
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .

Lucorafusp alfa	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Umikibart YYB-101; ABX101	c-Met/HGFR	Inflammation/Immunology
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Gimvekibart	Interleukin Related	Inflammation/Immunology
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting *IL-4Ra/CD124*. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .

Alcestobart	LAG-3	Inflammation/Immunology
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology
HY-P990951 is an NPR1-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Camtarkibart	Interleukin Related	Inflammation/Immunology
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Brivestobart	LAG-3	Inflammation/Immunology
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Mavrostobart	CD73	Inflammation/Immunology
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Comekibart	Interleukin Related	Inflammation/Immunology
HY-P990910 is an *IL4R*-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Ebribafusp alfa	CD3	Inflammation/Immunology
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Drotokibart SHR-1819	Interleukin Related	Inflammation/Immunology
HY-P990983 is an *IL4RA*-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Birinkibart	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Dalmitamig bsAb7075; REGN-7075; Marlotamig	EGFR	Inflammation/Immunology
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Solabafusp alfa	TNF Receptor	Inflammation/Immunology
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Safimestomig	CD47	Inflammation/Immunology
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Zamristobart	Human leukocyte immunoglobulin (Ig)-like receptors (LILR)	Inflammation/Immunology Cancer
Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

Olsutamig	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4].

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

Iparomlimab	PD-1/PD-L1	Cancer
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4]. x

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

Ubletamig	Mucin	Others
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

Amrecibart	Factor Xa	Cardiovascular Disease
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

Zemocimig	Factor Xa	Cardiovascular Disease
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

Lipustobart LZM-009	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .

Zigakibart BION-1301	TNF Receptor	Inflammation/Immunology Cancer
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

Anti-IL11RA Antibody (X209) EnX209	Interleukin Related	Inflammation/Immunology
Anti-IL11RA Antibody (X209) is a human-derived IgG4, κ type antibody inhibitor, targeting to human IL-11RA. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

CT140	PAI-1	Cardiovascular Disease
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

Eltrekibart LY-3041658	CXCR	Inflammation/Immunology
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Venanprubart LY-3361237	CD28	Inflammation/Immunology
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Pamvatamig	EGFR	Inflammation/Immunology
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Cat. No.	Product Name	Target	Research Area

HY-P99003

*Human IgG4* (S228P) kappa, Isotype Control** 5 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.

HY-P99106

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P99966

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

HY-P990770

Ucenprubart	Inhibitory Antibodies	Inflammation/Immunology
Ucenprubart is an anti-CD200R1 human IgG4κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991705

Nebaprubart	Fc Receptor (FcR)	Inflammation/Immunology
Nebaprubart is a humanized IgG4κ antibody targeting FCAR/CD89. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P990063

Mevonlerbart	Inhibitory Antibodies	Others
Mevonlerbart is an IgG4κ antibody targeting human Felcat allergen 1. Felcat allergen 1 is an allergen protein.

HY-P990062

Freneslerbart	Inhibitory Antibodies	Others
Freneslerbart is an IgG4κ antibody targeting Felcat allergen 1. Felcat allergen 1 is an allergen protein .

HY-P991710

Ponumkibart	Interleukin Related	Inflammation/Immunology
Ponumkibart is a humanized IgG4κ antibody targeting IL-17RB. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991694

Latarcibart	Inhibitory Antibodies	Cardiovascular Disease
Latarcibart is a humanized IgG4κ antibody targeting Protein S/PROS1. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991698

Liscastobart	PD-1/PD-L1	Cancer
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P99748

Nadecnemab	TGF-β Receptor	Inflammation/Immunology
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .

HY-P991721

Ticalicibart	PCSK9	Cardiovascular Disease
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .

HY-P991038

Zadoprubart	CD28	Inflammation/Immunology
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990960

Lucorafusp alfa	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990949

Umikibart YYB-101; ABX101	c-Met/HGFR	Inflammation/Immunology
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990970

Armocibart	Inhibitory Antibodies	Inflammation/Immunology
HY-P990970 is an TFPI-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991688

Gimvekibart	Interleukin Related	Inflammation/Immunology
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting *IL-4Ra/CD124*. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .

HY-P990968

Alcestobart	LAG-3	Inflammation/Immunology
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology
HY-P990951 is an NPR1-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991675

Camtarkibart	Interleukin Related	Inflammation/Immunology
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990976

Brivestobart	LAG-3	Inflammation/Immunology
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991009

Mavrostobart	CD73	Inflammation/Immunology
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990910

Comekibart	Interleukin Related	Inflammation/Immunology
HY-P990910 is an *IL4R*-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990955

Ebribafusp alfa	CD3	Inflammation/Immunology
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990952

Zaltenibart	Inhibitory Antibodies	Inflammation/Immunology
HY-P990952 is an MASP3-targeting IgG4κ type chimeric humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990983

Drotokibart SHR-1819	Interleukin Related	Inflammation/Immunology
HY-P990983 is an *IL4RA*-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990975

Birinkibart	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P990913

Dalmitamig bsAb7075; REGN-7075; Marlotamig	EGFR	Inflammation/Immunology
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991024

Solabafusp alfa	TNF Receptor	Inflammation/Immunology
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991023

Safimestomig	CD47	Inflammation/Immunology
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991727

Zamristobart	Human leukocyte immunoglobulin (Ig)-like receptors (LILR)	Inflammation/Immunology Cancer
Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99299

Lexatumumab HGS-ETR 2; ETR2-ST01	Apoptosis	Cancer
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

HY-P991708

Olsutamig	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4].

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99668

Iparomlimab	PD-1/PD-L1	Cancer
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma ^[4]. x

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P991166

Ubletamig	Mucin	Others
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991117

Amrecibart	Factor Xa	Cardiovascular Disease
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P991169

Zemocimig	Factor Xa	Cardiovascular Disease
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-P990072

Lipustobart LZM-009	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .

HY-P990070

Zigakibart BION-1301	TNF Receptor	Inflammation/Immunology Cancer
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

HY-P991219

Anti-IL11RA Antibody (X209) EnX209	Interleukin Related	Inflammation/Immunology
Anti-IL11RA Antibody (X209) is a human-derived IgG4, κ type antibody inhibitor, targeting to human IL-11RA. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991340

CT140	PAI-1	Cardiovascular Disease
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: